share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K：重大事件
美股SEC公告 ·  2024/10/03 16:32

Moomoo AI 已提取核心訊息

Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number...Show More
Aditxt, Inc., a biotech company, has filed a Form 8-K with the SEC, reporting several significant corporate developments. On October 1, 2024, Aditxt announced an amendment to its merger agreement with Evofem Biosciences, Inc., which included changes to the schedule and amounts of equity investments in Evofem. The third equity investment was adjusted to $720,000 and the fourth to $2.28 million, with the third investment's date extended to October 2, 2024. Additionally, Aditxt completed a reverse stock split at a ratio of 1-for-40, effective October 1, 2024, with the company's common stock trading on a split-adjusted basis from October 2, 2024. The reverse stock split consolidated every 40 shares of issued and outstanding common stock into one share, with a proportionate adjustment to the exercise price and number of shares issuable for stock options, restricted stock units, and warrants. The company's common stock continues to trade on the Nasdaq under the symbol 'ADTX' with a new CUSIP number. These corporate actions follow a series of amendments to the merger agreement and securities purchase agreements with Evofem, as detailed in previous SEC filings by Aditxt.
Aditxt，一家生物科技公司，已向美國證券交易委員會提交了一份8-K表格，報告了幾項重大的企業發展。2024年10月1日，Aditxt宣佈修訂了與evofem biosciences公司的合併協議，其中包括對evofem股權投資時間表和金額的更改。第三筆股權投資調整爲72萬美元，第四筆調整爲228萬美元，第三筆投資的日期延長至2024年10月2日。此外，Aditxt在2024年10月1日實施了1股拆40股的股票拆分，從2024年10月2日起生效，公司普通股從拆分調整後開始交易。股票拆分將已發行和流通普通股中的每40股合併爲1股，並對股票期權、限制性股票單位和認股權的行權價格和可發行股份數進行了相應調整。公司的普通股繼續在納斯達克交易，標的爲'ADTX'，具有新的CUSIP編號。這些企業行動是對與evofem的合併協議和證券購買協議進行的一系列修訂的後續，詳細信息已在Aditxt之前提交的美國證券交易委員會文件中披露。
Aditxt，一家生物科技公司，已向美國證券交易委員會提交了一份8-K表格，報告了幾項重大的企業發展。2024年10月1日，Aditxt宣佈修訂了與evofem biosciences公司的合併協議，其中包括對evofem股權投資時間表和金額的更改。第三筆股權投資調整爲72萬美元，第四筆調整爲228萬美元，第三筆投資的日期延長至2024年10月2日。此外，Aditxt在2024年10月1日實施了1股拆40股的股票拆分，從2024年10月2日起生效，公司普通股從拆分調整後開始交易。股票拆分將已發行和流通普通股中的每40股合併爲1股，並對股票期權、限制性股票單位和認股權的行權價格和可發行股份數進行了相應調整。公司的普通股繼續在納斯達克交易，標的爲'ADTX'，具有新的CUSIP編號。這些企業行動是對與evofem的合併協議和證券購買協議進行的一系列修訂的後續，詳細信息已在Aditxt之前提交的美國證券交易委員會文件中披露。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Sana Biotechnology
    SANA
    -- 4.300
    Vir Biotechnology
    VIR
    -- 12.480
    Silo Pharma
    SILO
    -- 1.710
    Compass Therapeutics
    CMPX
    -- 1.860
    NLS Pharmaceutics
    NLSP
    -- 2.4100

    解鎖榜首股票